ClinCapture to Provide Free EDC for Researchers Investigating COVID-19 Treatment
ClinCapture, Inc., a provider for Electronic Data Capture (EDC) systems and eClinical solutions, announced that it will begin offering EDC at no cost for specific clinical trials investigating COVID-19 Coronavirus. The decision to offer free EDC for BioPharma and Diagnostic companies conducting COVID-19 clinical trials was announced after the World Health Organization issued a statement that the confirmed number of COVID-19 cases has surpassed 100,000 globally.
ClinCapture is inspired by the response time, organization, and dedication to find solutions for COVID-19 demonstrated within the clinical research industry and would like to help these companies by offering free EDC for their trials. ClinCapture will be providing its Captivate EDC through the philanthropic Weidley's Wish program which normally provides EDC to non-profit organizations conducting Rare Disease/Orphan Disease trials.
"We are in a unique position in a unique point in history," said ClinCapture CEO Scott Weidley. "Our commitment to act now will have a dramatic effect on our ability to help in the future."
ClinCapture's Captivate EDC is a fully validated, cloud-hosted system designed to offer researchers more insight into their clinical data in order to bring treatments to market faster.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
